Virtual session to discover brainstrust’s PRIME initiative

1 min read

Patients and caregivers are invited to attend a virtual meeting to find out more about brainstrust’s Patient Research Involvement Movement (PRIME) initiative.

In partnership with Brain Tumour Research, PRIME is focused on ensuring clinical research projects are aligned with the needs of patients. Patient and public involvement and engagement (PPI&E) is key to attracting funding for research. PRIME has been set up to bring people with direct experience of living with a brain tumour into contact with the clinical research community where they can help shape studies and secure funding for research and clinical trials.

Our sister charity brainstrust understands how integral it is for brain tumour clinical research to have top level patient and public involvement guiding it in order to make the research relevant and meaningful for the person with the lived experience of the disease The comfort of the patient and their loved ones should be woven into the DNA of any study, which is provided by PRIME.

To ensure that PRIME continues to offer this gold standard of support to the clinical community, brainstrust is inviting anyone who is a patient or caregiver along to a virtual taster session held via Zoom on Friday 21st April, from noon until 1pm.

As a research partner, you would be able to attend Zoom meetings every two months which will include training on how to deliver PPI effectively, talks from clinicians and researchers working on new treatments, and further insights into the clinical research landscape.

Then, if there is an opportunity for a research partner to support a study, and you wanted to, you can do so with additional knowledge, insight and context.

To enquire about attending the virtual session, meet the brainstrust PRIME team and find out more about the initiative, contact

Related reading:

If you found this story interesting or helpful, sign up to our weekly e-news and keep up to date with all the latest from Brain Tumour Research.

Back to Latest News